Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives.
Epidermal growth factor receptor (EGFR) belongs to a family of receptors known as the ErbB family (ErbB tyrosine kinase receptors) which comprises four proteins encoded by the c-erbB proto-oncogene. EGFR is known to activate a cascade of multiple signaling pathways that facilitate tumor growth process. EGFR has been shown to be overexpressed in colorectal cancer patient populations but its prognostic value in colorectal cancer progression remains unclear. The development of a panel of EGFR inhibitors could reduce the proliferation of tumor cells when used alone or in combination with cytotoxic drugs or radiation. This review focuses on the potential role of EGFR signaling in the survival of colorectal tumor cells and the possible modulation of such signaling pathways by EGFR inhibitors so as to increase tumor control or render tumor cells more sensitive to conventional therapy.
Spano
J P
JP
SOMPS, Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, 47 boulevard de l'Hôpital, 75013 Paris, France. jean-philippe.spano@psl.ap-hop-paris.fr
Fagard
R
R
Soria
J-C
JC
Rixe
O
O
Khayat
D
D
Milano
G
G
D049109:Cell Proliferation; D002470:Cell Survival; D015179:Colorectal Neoplasms / Q000503:physiopathology* / Q000628:therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000502:physiology*; D006801:Humans; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D015398:Signal Transduction
C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D066246:ErbB Receptors